NanoCyte has announced that it will be presenting at
11:00, on Tuesday, September 20th, at Medtech Insight's "Investment In
Innovation (In3) EUROPE: A Preview of Medical Technology Companies"
Conference, taking place September 20-21, 2005, at The Crowne Plaza
Brussels City Centre Hotel in Brussels, Belgium.
NanoCyte has developed a unique drug delivery platform, leveraging marine extracted nano-injectors for immediate, active, device-less, minimally invasive, and completely painless topical drug delivery.
NanoCyte Advantages:
-- Flexible technology platform
NanoCyte offers a flexible technology platform with a broad range of therapeutic application potential.
-- Immediate active delivery
Once applied on the skin, NanoCyte microcapsules actively deliver the drug, through the stratum- corneum, into the epidermis; all in a matter of seconds.
-- Device-less application
NanoCyte bypasses the conventional needle, avoids using plastic, silicon, or other patches, probes, or devices.
-- Activation
NanoCyte microcapsules, kept as sterile powder, have been shown to maintain their inherent ability to generate an internal pressure of 200 atmospheres, leading to an injection acceleration of 40,000g., independent of any electronic, RF, or other power.
-- Painless administration
NanoCyte nano-injectors, less the 1micron in width penetrate the skin with no sensation at all.
-- Efficient delivery
As a topical application actually penetrating the stratum corneum, NanoCyte requires only minimal quantities of active pharmaceutical ingredient, thus reducing the risk of side effects. NanoCyte, applied on the skin as a cream, gel, or spray, can treat unlimited skin surface without the need for occlusion.
-- User friendly - no need for professional treatment
Self-applicable cream, gel, or spray.
NanoCyte is compatible with a wide range of compounds, organic and biological, small and macro. Indications and treatments include cosmeceuticals, dermatology, local pain, and various systemic indications.
NanoCyte microcapsules consisting of nano-injectors, are extracted from marine invertebrates (Hydra, Sea Anemone, Coral, etc). The outcome is microcapsules containing each a coiled microscopic nano-injector. Upon activation, the nano-injector unfolds to a length of up to 400u, penetrating the skin, and delivering the drug efficiently within a fraction of a second.
To date, NanoCyte had concluded a series of pre-clinical safety studies, including a 130 human volunteer safety (irritation and sensitization) study. NanoCyte had also concluded a series of in-vitro and in vivo efficacy studies. One major result was a 5 minute topical application of insulin leading to a reduction in glucose level similar to that achieved by a standard s.c. injection.
NanoCyte is now seeking additional strategic alliances and equity financing, to allow parallel development of pipeline applications while reducing time to market, and optimizing final application properties, in line with market needs.
Medtech Insight, a division of Windhover Information Inc., is the leading provider of business information and market intelligence for the medical technology marketplace. To register for the "Investment In Innovation EUROPE" conference or for more information on Medtech Insight, please call Kristy Grimes at 480-985-9512, e-mail kristy@medtechinsight.com, or visit www.medtechinsight.com.
NanoCyte has developed a unique drug delivery platform, leveraging marine extracted nano-injectors for immediate, active, device-less, minimally invasive, and completely painless topical drug delivery.
NanoCyte Advantages:
-- Flexible technology platform
NanoCyte offers a flexible technology platform with a broad range of therapeutic application potential.
-- Immediate active delivery
Once applied on the skin, NanoCyte microcapsules actively deliver the drug, through the stratum- corneum, into the epidermis; all in a matter of seconds.
-- Device-less application
NanoCyte bypasses the conventional needle, avoids using plastic, silicon, or other patches, probes, or devices.
-- Activation
NanoCyte microcapsules, kept as sterile powder, have been shown to maintain their inherent ability to generate an internal pressure of 200 atmospheres, leading to an injection acceleration of 40,000g., independent of any electronic, RF, or other power.
-- Painless administration
NanoCyte nano-injectors, less the 1micron in width penetrate the skin with no sensation at all.
-- Efficient delivery
As a topical application actually penetrating the stratum corneum, NanoCyte requires only minimal quantities of active pharmaceutical ingredient, thus reducing the risk of side effects. NanoCyte, applied on the skin as a cream, gel, or spray, can treat unlimited skin surface without the need for occlusion.
-- User friendly - no need for professional treatment
Self-applicable cream, gel, or spray.
NanoCyte is compatible with a wide range of compounds, organic and biological, small and macro. Indications and treatments include cosmeceuticals, dermatology, local pain, and various systemic indications.
NanoCyte microcapsules consisting of nano-injectors, are extracted from marine invertebrates (Hydra, Sea Anemone, Coral, etc). The outcome is microcapsules containing each a coiled microscopic nano-injector. Upon activation, the nano-injector unfolds to a length of up to 400u, penetrating the skin, and delivering the drug efficiently within a fraction of a second.
To date, NanoCyte had concluded a series of pre-clinical safety studies, including a 130 human volunteer safety (irritation and sensitization) study. NanoCyte had also concluded a series of in-vitro and in vivo efficacy studies. One major result was a 5 minute topical application of insulin leading to a reduction in glucose level similar to that achieved by a standard s.c. injection.
NanoCyte is now seeking additional strategic alliances and equity financing, to allow parallel development of pipeline applications while reducing time to market, and optimizing final application properties, in line with market needs.
Medtech Insight, a division of Windhover Information Inc., is the leading provider of business information and market intelligence for the medical technology marketplace. To register for the "Investment In Innovation EUROPE" conference or for more information on Medtech Insight, please call Kristy Grimes at 480-985-9512, e-mail kristy@medtechinsight.com, or visit www.medtechinsight.com.
© 2005 Business Wire
